Amsterdam: The European Medicines Agency’s human medicines committee wrapped up its May meeting with a batch of recommendations that touch some of the most closely watched corners of modern pharmacology. Eight new medicines won a positive opinion from the Committee for Medicinal Products for Human Use, and another thirteen existing products were cleared for expanded uses. None of these decisions are final. They now travel to the European Commission, which usually converts a positive opinion into a marketing authorisation within two to three months.
The headline of the May round is a familiar name in an unfamiliar form. The committee backed an extension for semaglutide, the active ingredient behind some of the best-selling weight-management injections, to be sold as a daily oral tablet. If the Commission agrees, it would be the first glucagon-like peptide receptor agonist for weight management designed to be swallowed rather than injected. For patients who balk at weekly needles, the practical difference is considerable, and for health systems already wrestling with surging demand it raises fresh questions about budgets and prescribing rules.
Less prominent but arguably more consequential for the patients involved were two recommendations aimed at rare and grievous conditions. The committee endorsed nerandomilast for idiopathic pulmonary fibrosis and progressive pulmonary fibrosis, two diseases in which lung tissue scars relentlessly and irreversibly. Treatment options have been thin, and a new mechanism offers a measure of hope where there has been little. The committee also recommended a conditional marketing authorisation for alpelisib to treat severe forms of a rare overgrowth syndrome driven by a specific genetic mutation. Conditional authorisations let medicines reach desperate patients before the full evidence package is complete, on the understanding that the manufacturer keeps gathering data.
The arithmetic of the meeting matters as much as the individual drugs. Indication extensions, the thirteen quieter decisions, rarely make headlines, yet they often deliver the broadest public-health gains by letting established medicines reach new groups of patients without the cost and delay of a fresh approval. Taken together, the May output continues a pattern that industry analysts have flagged for months: the centre of gravity in European drug development is shifting toward rare diseases, metabolic conditions and reformulations of proven molecules.
That shift carries trade-offs. Conditional and accelerated pathways speed access but lean on post-marketing commitments that regulators must then police. Reformulated blockbusters expand convenience but can entrench the market position of a handful of firms. And the widening gap between what the agency recommends and what national systems can actually afford means a positive opinion in the Netherlands does not guarantee a prescription in Riga or Lisbon. Reimbursement remains a national competence, and the divergence is growing.
For now, the agency has done its part of the job. The recommendations head to the Commission, and the genuinely difficult conversations, about price, about which patients qualify and about how to monitor medicines once they are on the market, move to capitals. The science committee can judge whether a medicine works and is safe enough to sell. Whether Europeans can get hold of it is a separate question, and one the agency cannot answer.
